We are live on ! Find out more
CPXX

CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX

Delisted

CPXX was delisted on the 11th of July, 2016.

0 hedge funds and large institutions have $0 invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 117 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1190 (-119)

100% less funds holding in top 10

Funds holding in top 10: 60 (-6)

100% less capital invested

Capital invested by funds: $944M → $0 (-$944M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 117

Holders
Holders Change
-119
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
117
Calls
Puts
Net Calls
Net Calls Change

CPXX Hedge Fund Activity: Q3 2016 in Review

0 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q3 2016, worth a combined $0 — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 117 funds closed out of CPXX and 0 opened new positions — a net loss of 117 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Caxton Corporation, exiting entirely with an estimated $67.4M sold.

  • 0 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q3 2016, down from 119 in Q2 2016.
  • Funds reported $0 of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q3 2016, down 100% quarter-over-quarter.
  • 0 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q3 2016 and 117 closed out, a net change of -117 holders.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q3 2016 was Caxton Corporation, an estimated $67.4M sold.

Based on aggregated 13F filings for Q3 2016.